Geoffrey Yuyat Ku

20PUBLICATIONS
144CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 15, 2025
Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396).

David Restle, Alfredo Amador-Molina, Kyohei Misawa

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.

Kohei Shitara, Sylvie Lorenzen, Jin Li

|Apr 29, 2025
Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.

Henry S Walch, Raktim Borpatragohain, Justin Jee

|Sep 05, 2024
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Sarina Piha-Paul, Shane A Olwill, Erika Hamilton

|Sep 12, 2023
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer.

Melissa A Lumish, Henry Walch, Steven B Maron

Pageof 4

Frequent Collaborators

4 joint publications

Abraham Wu

3 joint publications

David B Solit

3 joint publications

Henry Walch

3 joint publications

Steven B Maron